415 related articles for article (PubMed ID: 26087192)
1. Long noncoding RNAs and neuroblastoma.
Pandey GK; Kanduri C
Oncotarget; 2015 Jul; 6(21):18265-75. PubMed ID: 26087192
[TBL] [Abstract][Full Text] [Related]
2. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
3. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.
Liu PY; Erriquez D; Marshall GM; Tee AE; Polly P; Wong M; Liu B; Bell JL; Zhang XD; Milazzo G; Cheung BB; Fox A; Swarbrick A; Hüttelmaier S; Kavallaris M; Perini G; Mattick JS; Dinger ME; Liu T
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906397
[TBL] [Abstract][Full Text] [Related]
4. Identification of prognostic long noncoding RNAs associated with spontaneous regression of neuroblastoma.
Meng X; Fang E; Zhao X; Feng J
Cancer Med; 2020 Jun; 9(11):3800-3815. PubMed ID: 32216054
[TBL] [Abstract][Full Text] [Related]
5. Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory Axis.
Mondal T; Juvvuna PK; Kirkeby A; Mitra S; Kosalai ST; Traxler L; Hertwig F; Wernig-Zorc S; Miranda C; Deland L; Volland R; Bartenhagen C; Bartsch D; Bandaru S; Engesser A; Subhash S; Martinsson T; Carén H; Akyürek LM; Kurian L; Kanduri M; Huarte M; Kogner P; Fischer M; Kanduri C
Cancer Cell; 2018 Mar; 33(3):417-434.e7. PubMed ID: 29533783
[TBL] [Abstract][Full Text] [Related]
6. HOXD-AS1 is a novel lncRNA encoded in HOXD cluster and a marker of neuroblastoma progression revealed via integrative analysis of noncoding transcriptome.
Yarmishyn AA; Batagov AO; Tan JZ; Sundaram GM; Sampath P; Kuznetsov VA; Kurochkin IV
BMC Genomics; 2014; 15 Suppl 9(Suppl 9):S7. PubMed ID: 25522241
[TBL] [Abstract][Full Text] [Related]
7. Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.
Mouraviev V; Lee B; Patel V; Albala D; Johansen TE; Partin A; Ross A; Perera RJ
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):14-20. PubMed ID: 26503110
[TBL] [Abstract][Full Text] [Related]
8. Targeting long noncoding RNAs in neuroblastoma: Progress and prospects.
Ataei A; Tahsili M; Hayadokht G; Daneshvar M; Mohammadi Nour S; Soofi A; Masoudi A; Kabiri M; Natami M
Chem Biol Drug Des; 2023 Sep; 102(3):640-652. PubMed ID: 37291742
[TBL] [Abstract][Full Text] [Related]
9. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
10. 59-gene prognostic signature sub-stratifies high-risk neuroblastoma patients.
Vermeulen J; De Preter K; Laureys G; Speleman F; Vandesompele J
Lancet Oncol; 2009 Nov; 10(11):1030. PubMed ID: 19880060
[No Abstract] [Full Text] [Related]
11. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNAs in digestive system cancers: Functional roles, molecular mechanisms, and clinical implications (Review).
Fu M; Zou C; Pan L; Liang W; Qian H; Xu W; Jiang P; Zhang X
Oncol Rep; 2016 Sep; 36(3):1207-18. PubMed ID: 27431376
[TBL] [Abstract][Full Text] [Related]
13. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
14. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
15. Long Noncoding RNA pancEts-1 Promotes Neuroblastoma Progression through hnRNPK-Mediated β-Catenin Stabilization.
Li D; Wang X; Mei H; Fang E; Ye L; Song H; Yang F; Li H; Huang K; Zheng L; Tong Q
Cancer Res; 2018 Mar; 78(5):1169-1183. PubMed ID: 29311158
[TBL] [Abstract][Full Text] [Related]
16. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
17. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA in prostate, bladder, and kidney cancer.
Martens-Uzunova ES; Böttcher R; Croce CM; Jenster G; Visakorpi T; Calin GA
Eur Urol; 2014 Jun; 65(6):1140-51. PubMed ID: 24373479
[TBL] [Abstract][Full Text] [Related]
19. Risk estimation of neuroblastoma patients using molecular markers.
Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
[TBL] [Abstract][Full Text] [Related]
20. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients.
Combaret V; Audoynaud C; Iacono I; Favrot MC; Schell M; Bergeron C; Puisieux A
Cancer Res; 2002 Jul; 62(13):3646-8. PubMed ID: 12097268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
